AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22539780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (STreSS), nine 3.5 h sessions over 4 months
Number of subjects: 120
Study 22539780 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (management by primary care physician or medical specialist)
Number of subjects: 120
Study 20679151 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk naturally enriched in CLA (4.2%) containing c-9, t-11 providing 1.3 g/d of CLA
Number of subjects: 0
Study 20679151 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk enriched with a 4.2% synthetic mixture of t-10, c-12 and c-9, t-11 CLA isomers providing 1.3 g/d of CLA
Number of subjects: 0
Study 20679151 — intervention group
Group type: COMPARATOR
Intervention: Untreated milk (control) providing 0.2 g/d CLA
Number of subjects: 0
Study 20679151 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk enriched with CLA (both types)
Number of subjects: 0
Study 17564282 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mcg nebulized beclomethasone dipropionate once daily (o.d. group)
Number of subjects: 65
Study 17564282 — intervention group
Group type: COMPARATOR
Intervention: 400 mcg nebulized beclomethasone dipropionate twice daily (b.i.d. group)
Number of subjects: 65
Study 16109532 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70
Study 16109532 — intervention group
Group type: COMPARATOR
Intervention: Routine method (Control)
Number of subjects: 70
Study 12441019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg daily
Number of subjects: 0
Study 12441019 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 0
Study 10419077 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol 5/50 mg
Number of subjects: 212
Study 10419077 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 212
Study 7759064 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (blood glucose level clamped at 12.2 mmol/l for 4 hours by infusing 20% glucose solution)
Number of subjects: 0
Study 7759064 — intervention group
Group type: COMPARATOR
Intervention: Saline control (isotonic saline infusion over 4 hours)
Number of subjects: 0
Study 2185694 — intervention group
Group type: EXPERIMENTAL
Intervention: KRN 8601 at 50 micrograms/m2
Number of subjects: 36
Study 2185694 — intervention group
Group type: EXPERIMENTAL
Intervention: KRN 8601 at 100 micrograms/m2
Number of subjects: 36
Study 2185694 — intervention group
Group type: COMPARATOR
Intervention: Control phase without KRN 8601 treatment
Number of subjects: 36
Study 311515 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (aortocoronary bypass surgery)
Number of subjects: 0
Study 311515 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study 30972934 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide therapy for 16 weeks
Number of subjects: 0
Study 30972934 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetic subjects
Number of subjects: 0
Study 29693429 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (5 mmol per day)
Number of subjects: 10
Study 29693429 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation
Number of subjects: 10
Study 29693429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 26635348 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (∼8 mmol NO3 (‐))
Number of subjects: 8
Study 26635348 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice + mouthwash (Beet+MW)
Number of subjects: 8
Study 26635348 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate‐depleted Beet)
Number of subjects: 8
Study 25046624 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg twice daily)
Number of subjects: 56
Study 25046624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 25046624 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 56
Study 20157905 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component sleep therapy intervention
Number of subjects: 0
Study 20157905 — intervention group
Group type: COMPARATOR
Intervention: Basic sleep hygiene education
Number of subjects: 0
Study 17286094 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC exercise program
Number of subjects: 32
Study 17286094 — intervention group
Group type: COMPARATOR
Intervention: TRAD exercise program
Number of subjects: 32
Study 16083948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent self-catheterisation (ISC)
Number of subjects: 40
Study 16083948 — intervention group
Group type: COMPARATOR
Intervention: Supra-pubic catheterisation (SPC)
Number of subjects: 40
Study 12690368 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenons lidocaine injection (1 mL of 2% lidocaine)
Number of subjects: 31
Study 12690368 — intervention group
Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 31
Study 12690368 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenons lidocaine injection
Number of subjects: 31
Study 10965640 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered intervention (Student Bodies [SB])
Number of subjects: 76
Study 10965640 — intervention group
Group type: COMPARATOR
Intervention: Classroom-delivered intervention (Body Traps [BT])
Number of subjects: 76
Study 10965640 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 76
Study 8791969 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 192
Study 8791969 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 80 mg
Number of subjects: 192
Study 8791969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing schedules
Number of subjects: 192
Study 1620911 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified formulation of inhaled salbutamol using a new inhaler device
Number of subjects: 11
Study 1620911 — intervention group
Group type: COMPARATOR
Intervention: Conventional salbutamol
Number of subjects: 11
Study 1620911 — intervention group
Group type: COMPARATOR
Intervention: New inhaler device (Rotahaler)
Number of subjects: 11
Study 6391830 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100 to 400 mg daily)
Number of subjects: 111
Study 6391830 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (30 to 120 mg daily)
Number of subjects: 111
Study 6391830 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 111
Study 30282447 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14 (administered every 2 weeks)
Number of subjects: 702
Study 30282447 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP-21 (administered every 3 weeks)
Number of subjects: 702
Study 30282447 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14 and R-CHOP-21
Number of subjects: 702
Study 29214483 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + active tDCS
Number of subjects: 192
Study 29214483 — intervention group
Group type: COMPARATOR
Intervention: CBT + sham‐tDCS
Number of subjects: 192
Study 29214483 — intervention group
Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 192
Study 26271678 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy load (25 kg backpack)
Number of subjects: 15
Study 26271678 — intervention group
Group type: COMPARATOR
Intervention: Unloaded condition (no backpack)
Number of subjects: 15
Study 24491414 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml kg(‐1) of 0.15% ropivacaine with 0.1 mg kg(‐1) dexamethasone (Group D)
Number of subjects: 80
Study 24491414 — intervention group
Group type: COMPARATOR
Intervention: 1.5 ml kg(‐1) of 0.15% ropivacaine (Group C)
Number of subjects: 80
Study 22348439 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA meal (high-oleic sunflower oil enriched with 4.7 g of DHA)
Number of subjects: 22
Study 22348439 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA meal (high-oleic sunflower oil enriched with 4.7 g of EPA)
Number of subjects: 22
Study 22348439 — intervention group
Group type: COMPARATOR
Intervention: Control meal (high-oleic sunflower oil only)
Number of subjects: 22
Study 20201666 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreat group (23 residents)
Number of subjects: 49
Study 20201666 — intervention group
Group type: COMPARATOR
Intervention: Control group (26 residents)
Number of subjects: 49
Study 17494795 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 14
Study 17494795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia
Number of subjects: 14
Study 16153508 — intervention group
Group type: EXPERIMENTAL
Intervention: EDPR gradient > 5.0 mm Hg
Number of subjects: 741
Study 16153508 — intervention group
Group type: EXPERIMENTAL
Intervention: EDPR gradient
Number of subjects: 741
Study 12041862 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified TCu380A insertion technique (shortened applicator by 1.5 cm)
Number of subjects: 169
Study 12041862 — intervention group
Group type: COMPARATOR
Intervention: Unmodified TCu380A insertion technique
Number of subjects: 169
Study 9710393 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 microg x kg(‐1) x min(‐1))
Number of subjects: 23
Study 9710393 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (2 microg x kg(‐1) x min(‐1))
Number of subjects: 23
Study 9710393 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 23
Study 9710393 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 23
Study 7996626 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral vestibular neurectomy
Number of subjects: 6
Study 3179579 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal at 20 degrees C
Number of subjects: 8
Study 3179579 — intervention group
Group type: COMPARATOR
Intervention: Test meal at 37 degrees C
Number of subjects: 8
Study 3179579 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal at 4 degrees C
Number of subjects: 8
Study 3179579 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal at 55 degrees C
Number of subjects: 8
Study 30446424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive
Number of subjects: 96
Study 30446424 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture
Number of subjects: 96
Study 30369379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (20ml/50mg of 0.25%)
Number of subjects: 94
Study 30369379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 94
Study 26201934 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso-jejunal (NJ) fluid resuscitation using oral hydration solution (ORS: 20 ml/kg bolus and then 3 mL/kg/h)
Number of subjects: 49
Study 26201934 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) fluid resuscitation using Ringer Lactate (RL infusion at same rate)
Number of subjects: 49
Study 26201934 — intervention group
Group type: EXPERIMENTAL
Intervention: Naso-jejunal (NJ) fluid resuscitation using oral hydration solution (ORS)
Number of subjects: 49
Study 26201934 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) fluid resuscitation using Ringer Lactate (RL)
Number of subjects: 49
Study 25440210 — intervention group
Group type: EXPERIMENTAL
Intervention: Occiput-atlas-axis global manipulation (OAA)
Number of subjects: 84
Study 25440210 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both techniques
Number of subjects: 84
Study 25440210 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboccipital soft tissue inhibition
Number of subjects: 84
Study 25440210 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 22795809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous bisglycinate chelate, 28 mg per day for 20 days, then 14 mg per day for 40 days (12 patients)
Number of subjects: 24
Study 22795809 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulfate, 105 mg per day for 60 days (12 patients)
Number of subjects: 24
Study 22795809 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) related to treatments
Number of subjects: 24
Study 20587101 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 28
Study 20587101 — intervention group
Group type: COMPARATOR
Intervention: Supplemental oxygen
Number of subjects: 28
Study 18039501 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium as sodium selenite (4000 microg on the first day, 1000 microg/day for the next 9 days)
Number of subjects: 0
Study 18039501 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 18039501 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose selenium administration
Number of subjects: 0
Study 18039501 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of selenium
Number of subjects: 0
Study 16128875 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic muscle stretch (with and without weight bearing)
Number of subjects: 87
Study 16128875 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic muscle stretch
Number of subjects: 87
Study 16128875 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 87
Study 12034949 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (200 mg intravenously)
Number of subjects: 100
Study 12034949 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 100
Study 9807972 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 69
Study 9807972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 7667771 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 345
Study 7667771 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 345
Study 7667771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 345
Study 7667771 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 345
Study 2681320 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase treatment
Number of subjects: 331
Study 2681320 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 331
Study 816842 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of disodium cromoglycate (DSCG)
Number of subjects: 14
Study 816842 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of disodium cromoglycate (DSCG)
Number of subjects: 14
Study 816842 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of disodium cromoglycate (DSCG) four times daily for 2 days
Number of subjects: 14
Study 816842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 6453695 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% benzoyl peroxide gel
Number of subjects: 50
Study 6453695 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide gel
Number of subjects: 50
Study 6453695 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% benzoyl peroxide gel
Number of subjects: 50
Study 6453695 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger or milder concentration of benzoyl peroxide gel
Number of subjects: 50
Study 31269122 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol package (lip hydration and ice popsicles)
Number of subjects: 120
Study 31269122 — intervention group
Group type: COMPARATOR
Intervention: Non-menthol measures (lip hydration and ice popsicles)
Number of subjects: 120
Study 29016980 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care (initial 20-min of behavioural change counselling, followed by three sessions of Motivational Enhancement Therapy and referral to local alcohol services)
Number of subjects: 100
Study 29016980 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (5-min of brief advice)
Number of subjects: 100
Study 29016980 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped Care
Number of subjects: 100
Study 29016980 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention
Number of subjects: 100
Study 25633662 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg/linagliptin 5 mg
Number of subjects: 137
Study 25633662 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg/linagliptin 5 mg
Number of subjects: 137
Study 25633662 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg
Number of subjects: 137
Study 25633662 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg
Number of subjects: 137
Study 25633662 — intervention group
Group type: COMPARATOR
Intervention: linagliptin 5 mg
Number of subjects: 137
Study 24382548 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface Electrical Stimulation Group (SESG)
Number of subjects: 48
Study 24382548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal Electrical Stimulation Group (IVESG)
Number of subjects: 48
Study 24382548 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 48
Study 22474066 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 120 mg once daily for 4 weeks (non-atorvastatin group)
Number of subjects: 24
Study 22474066 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib 120 mg twice daily for 4 weeks (non-atorvastatin group)
Number of subjects: 24
Study 22474066 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg daily (control group)
Number of subjects: 24
Study 22474066 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks (control group)
Number of subjects: 24
Study 19938918 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (mean Blood Alcohol Concentration [BAC] = .10) with enhanced self-focused attention
Number of subjects: 40
Study 19938918 — intervention group
Group type: EXPERIMENTAL
Intervention: Veridical control drink with enhanced self-focused attention
Number of subjects: 40
Study 19938918 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (mean Blood Alcohol Concentration [BAC] = .10) without enhanced self-focused attention
Number of subjects: 40
Study 19938918 — intervention group
Group type: COMPARATOR
Intervention: Veridical control drink without enhanced self-focused attention
Number of subjects: 40
Study 17468881 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue trial of 30‐s maximal static exercise of the knee flexors
Number of subjects: 16
Study 17468881 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no exercise)
Number of subjects: 16
Study 14737854 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/day)
Number of subjects: 305
Study 14737854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 11335697 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton MR spectroscopy with metabolite-nulling in acute lesions
Number of subjects: 30
Study 9727782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulphate (3 mL, 3.2% solution, 95 mg)
Number of subjects: 33
Study 9727782 — intervention group
Group type: COMPARATOR
Intervention: Nebulized salbutamol (3 mL, 2.5 mg)
Number of subjects: 33
Study 8001355 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux disease activity index
Number of subjects: 0
Study 8001355 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy and pH monitoring
Number of subjects: 0
Study 3241289 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenobarbital (MPB) 3 x 10 mg/kg on the first day
Number of subjects: 0
Study 3241289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31822498 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg) in combination with taselisib (4 mg)
Number of subjects: 0
Study 31822498 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide alone
Number of subjects: 0
Study 31822498 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enzalutamide and taselisib
Number of subjects: 0
Study 31822498 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide and taselisib in Luminal AR (LAR) TNBC subtype
Number of subjects: 0
Study 31055061 — intervention group
Group type: EXPERIMENTAL
Intervention: NMT (Neuromuscular Training) program for 8 weeks, 6 weeks of which included 18 sessions lasting approximately 30 minutes each
Number of subjects: 40
Study 31055061 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 27838369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-exercise group (supervised resistance exercise at home for 20-40 min, three times per week for 12 weeks)
Number of subjects: 23
Study 27838369 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-exercise group
Number of subjects: 23
Study 27838369 — intervention group
Group type: COMPARATOR
Intervention: Control group (maintained lifestyle without intervention)
Number of subjects: 23
Study 25451617 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-infant psychoanalytic treatment (MIP group)
Number of subjects: 66
Study 25451617 — intervention group
Group type: COMPARATOR
Intervention: Child Health Center care (CHCC group)
Number of subjects: 66
Study 23551822 — intervention group
Group type: COMPARATOR
Intervention: Non-alcohol (BAC equal to 0‰)
Number of subjects: 499
Study 23551822 — intervention group
Group type: COMPARATOR
Intervention: Legal alcohol (BAC greater than 0 up to 0.8‰)
Number of subjects: 499
Study 23551822 — intervention group
Group type: COMPARATOR
Intervention: Illegal alcohol (BAC greater than 0.8‰)
Number of subjects: 499
Study 20929723 — intervention group
Group type: EXPERIMENTAL
Intervention: APF + PD
Number of subjects: 12
Study 20929723 — intervention group
Group type: EXPERIMENTAL
Intervention: APF + FD
Number of subjects: 12
Study 20929723 — intervention group
Group type: COMPARATOR
Intervention: 1100‐ppm‐F dentifrice (FD)
Number of subjects: 12
Study 20929723 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (PD)
Number of subjects: 12
Study 19423387 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS on primary motor cortex (M1)
Number of subjects: 29
Study 19423387 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS on calcarine cortex
Number of subjects: 29
Study 19423387 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 29
Study 16682727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral topotecan 2.3 mg/m2/d on days 1 to 5
Number of subjects: 829